2,4-dimethyl-5-nitrobenzenesulfonyl chloride | 71474-35-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dimethyl-5-nitrobenzenesulfonyl chloride
• 英文别名: 2,4-Dimethyl-5-nitrobenzene-1-sulfonyl chloride
• CAS: 71474-35-6
• 化学式: C₈H₈ClNO₄S
• mdl: MFCD19200208
• 分子量: 249.675
• InChiKey: WQYQATRTLGVNEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-dimethyl-5-nitrobenzenesulfonyl chloride 在 哌啶 、 苯 作用下， 生成 (5-nitro-2,4-di-trans(?)-styryl-phenyl)-phenyl sulfone
  参考文献：
  名称：

  Reactivity of Methyl Groups in Some Derivatives of m-Xylene and Toluene

  摘要：

  DOI：

  10.1021/ja01575a035
• 作为产物：
  描述：

  1,3-二甲基-4-硝基苯 在 氯磺酸 、 sodium chloride 作用下， 以65%的产率得到2,4-dimethyl-5-nitrobenzenesulfonyl chloride
  参考文献：
  名称：

  芳烃磺酰氯的丙烷分解：磺酰硫处的亲核取代

  摘要：

  我们研究了在303-323 K时丙-1-醇和丙-2-醇对芳烃磺酰氯的溶剂分解机理。动力学曲线适合一阶动力学。反应性随供电子取代基的增加而增加。芳烃磺酰氯的邻烷基取代衍生物显示出增加的反应性，但这种“正向”邻效应的起源仍不清楚。可能，邻位甲基限制了绕C键的旋转，从而促进了亲核试剂的攻击。就亲核性空间效应而言，未发现丙-1-醇和丙-2-醇的相关反应性变化。所有底物的等动力学关系的存在表明该系列的单一机制。两种醇中所有底物的溶剂分解反应均显示等速温度（T iso）接近工作温度范围，这表明该过程受到次级反应性因素的影响，该因素可能是TS中的空间性质。溶剂化在该反应中起重要作用，调节反应性。在一些情况下，存在吨-Bu代替我在对位位置导致第一溶剂化壳的变化，从而增加了反应能量（约1 kJ·mol -1）。所得结果表明，芳烃磺酰氯对丙-1-醇和丙-2-醇的溶剂化动力学机制与在MeOH和EtOH中相同，其中双分子亲核取代（S

  DOI：

  10.1002/poc.3753

文献信息

• N-ARYLAMIDINE-SUBSTITUTED TRIFLUOROETHYL SULFIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES
  申请人：BAYER CROPSCIENCE AG

  公开号：US20140315898A1

  公开（公告）日：2014-10-23

  The present invention relates to novel N-arylamide-substituted trifluoroethyl sulfide derivatives of the formula (I) in which X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , n have the meanings given in the description—to their use as acaricides and insecticides for controlling animal pests and to processes and intermediates for their preparation

  本发明涉及公式（I）中的新型N-芳酰胺取代三氟乙基硫醚衍生物，其中X1、X2、X3、X4、R1、R2、R3、n的含义如描述所示—它们作为杀螨剂和杀虫剂用于控制动物害虫，并涉及其制备的过程和中间体。
• [EN] SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF<br/>[FR] INHIBITEURS D'ADAPTATEUR DE SUBSTRAT DE PRMT5 ET LEURS UTILISATIONS
  申请人：BROAD INST INC

  公开号：WO2022032144A1

  公开（公告）日：2022-02-10

  Provided herein are compounds that modulate PRTM5 activity. The compounds may inhibit the binding PRMT5 with a PRMT5 substrate adaptor. The compounds can modulate PRMT5 methyltransferase activity, modulate transcription of a gene regulated by PRMT5, modulate chromatin structure regulation, modulate cellular differentiation, and/or modulate mRNA splicing, e.g., by disrupting binding of PRMT5 with a PRMT5 substrate adaptor. Also provided are pharmaceutical compositions comprising the compounds, methods of modulating PRTM5 activity, and methods of treating disease (e.g., cancer) in a subject by administering a compound or composition described herein.

  本文提供了调节PRTM5活性的化合物。这些化合物可以抑制PRMT5与PRMT5底物适配器的结合。这些化合物可以调节PRMT5甲基转移酶活性，调节PRMT5调控的基因的转录，调节染色质结构调节，调节细胞分化，以及/或通过破坏PRMT5与PRMT5底物适配器的结合来调节mRNA剪接。此外，还提供了包含这些化合物的制药组合物，调节PRTM5活性的方法，以及通过给予本文所述的化合物或组合物治疗疾病（例如癌症）的方法。
• Ureylene phenylene anionic naphthalene-sulfonic acids, their use as complement system inhibitors in a body fluid and process for their preparation
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0008154A1

  公开（公告）日：1980-02-20

  The present invention provides novel ureylene phenylene anionic naphthalenesulfonic acids, which have complement-inhibiting properties and which may be represented by the general formula: wherein X and Y are each selected from the group consisting of -CO- and -SO2-; R and R3 are each selected from the group consisting of hydrogen, methyl and -S03A, wherein A is a pharmaceutically acceptable salt cation; R, and R4 are each selected from the group consisting of hydrogen and -COOB. wherein B is selected from the group consisting of hydrogen and a pharmaceutically acceptable salt cation; R2 and Rs are each selected from the group consisting of hydrogen and methyl; with the proviso that R. R,, R2, R3, R4 and R5 may not all be hydrogen; with the second proviso that when X and Y are both -CO- and R2 is methyl, then R, R,, R3, R. and Rs may not all be hydrogen; and with the third proviso that no phenyl moiety can contain both -SO3A and -COOB. The corresponding amine compounds of the formula below are novel intermediates for the novelureylene compounds above:

  本发明提供了具有补体抑制特性的新型脲苯基阴离子萘磺酸，其可由通式表示： 其中 X 和 Y 各自选自由 -CO- 和 -SO2- 组成的组；R 和 R3 各自选自由氢、甲基和 -S03A 组成的组，其中 A 是药学上可接受的阳离子盐；R 和 R4 各自选自由氢和 -COOB 组成的组。其中 B 选自氢和药学上可接受的盐阳离子组成的组；R2 和 Rs 各选自氢和甲基组成的组；但书中 R、R、R2、R3、R4 和 R5 不一定都是氢；第二个但书是当 X 和 Y 都是-CO-且 R2 是甲基时，则 R、R、R3、R.和 Rs 不一定都是氢；第三个但书是任何苯基都不能同时含有-SO3A 和-COOB。 下式中相应的胺化合物是上述新脲烯类化合物的新型中间体：
• Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability
  作者：Ian Sellitto、Bertrand Le Bourdonnec、Karin Worm、Allan Goodman、Markku A. Savolainen、Guo-Hua Chu、Christopher W. Ajello、Christopher T. Saeui、Lara K. Leister、Joel A. Cassel、Robert N. DeHaven、Christopher J. LaBuda、Michael Koblish、Patrick J. Little、Bernice L. Brogdon、Steven A. Smith、Roland E. Dolle

  DOI：10.1016/j.bmcl.2009.10.062

  日期：2010.1

  A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability pro. le in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB2 agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain. (C) 2009 Elsevier Ltd. All rights reserved.
• DE83997
  申请人：——

  公开号：——

  公开（公告）日：——